Depo-Provera Lawsuit [February 2026 Update]

November 26th, 2025: Depo-Provera Brain Tumor Lawsuits Surpass 2,000 Amid Growing Safety Concerns

More than 2,000 lawsuits have now been filed against Pfizer and other drugmakers over allegations that Depo-Provera birth control shots caused women to develop intracranial meningiomas, a type of brain tumor.

The surge in filings follows recent studies linking Depo-Provera to a 5.5x increased risk of brain tumors.

Plaintiffs claim the drug companies failed to warn users and the medical community for decades.

As of November 17, there are:

• 1,633 cases consolidated in the Northern District of Florida
• 322 plaintiffs across 13 cases in the Delaware state court
• 83 plaintiffs in 75 cases in the New York state court
• Additional cases filed in California (24), Illinois (5), Pennsylvania (2), and New Mexico (1)

The litigation is in early stages, with general causation discovery underway and a group of bellwether trials expected to be selected. Over 9,500 more claims remain under investigation.

Nov 5th, 2025: Depo-Provera MDL Deadlines Extended Six Weeks to Sync With State Cases

Judge M. Casey Rodgers has extended key deadlines in the Depo-Provera brain tumor MDL by about six weeks, enabling the federal proceedings to sync with coordinated cases in New York and Delaware state courts.

Under the revised schedule, plaintiffs’ general-causation expert disclosures are due on December 1, 2025, defendants’ disclosures by January 9, 2026; and all expert depositions must be completed by February 20, 2026.

Any Rule 702 challenges to specialist testimony must be filed by March 22, 2026.

The adjustment comes after a conference on October 24 between federal and state court judges overseeing the litigation.

The extension provides both sides more time to review evidence on how long a product is used and the delay between Depo-Provera injections and tumor development.

Judge Rodgers formalized the updated timeline in Case Management Order No. 7, issued on October 30, 2025.

The next MDL status conference is scheduled for November 21, 2025.

November 3rd, 2025: November 2025 JPML Update

The number of Depo-Provera claims increased slightly from 1,222 in October to 1,225 in November.

Plaintiffs allege the birth control injection caused osteoporosis and other bone-density complications after prolonged use.

The increase suggests ongoing interest from potential claimants and continued legal activity around long-term side effects.

The litigation remains in early phases with filings still coming into the docket.

Our attorneys are actively accepting new clients for the Depo-Provera Lawsuit, helping them gather evidence of their Depo-Provera usage and assess the impact of their brain tumors in financial terms. 

Contact us today for a free consultation, or use the chat feature on this page to find out if you qualify for the Depo-Provera Lawsuit instantly.

October 27th, 2025: New Lawsuits Allege Pfizer’s Depo-Provera Caused Brain Tumors

Three women have filed lawsuits in Florida federal court alleging that Pfizer’s contraceptive injection, Depo-Provera, caused them to develop brain tumors.

The cases join a rapidly growing multidistrict litigation that has expanded from 70 to over 1,300 suits since February.

The plaintiffs claim they used the drug for years before developing neurological symptoms such as vertigo, headaches, and vision problems that preceded tumor diagnoses.

Their complaints accuse Pfizer of failing to warn patients about the risk despite mounting scientific evidence connecting Depo-Provera and hormonal progestins to tumor development.

Pfizer maintains the claims are preempted by federal law, arguing that the FDA blocked its attempts to update warning labels and that Depo-Provera remains a safe, FDA-approved contraceptive used by millions worldwide.

Plaintiffs, however, argue the drug’s dosage is excessively high and that Pfizer prioritized profits over safety.

The outcome of these early cases could shape the broader litigation surrounding long-term Depo-Provera use and women’s health risks.

October 23rd, 2025: Depo-Provera Brain Tumor MDL Advances Toward Expert Testimony Phase

The Depo-Provera multidistrict litigation (MDL No. 3140) continues to progress as parties coordinate with parallel cases in Delaware and New York state courts.

The MDL currently includes 1,346 total cases, with 1,332 complaints deemed complete and 509 plaintiffs submitting full proof of use and meningioma diagnosis documentation.

The parties are aligning their general causation schedules across jurisdictions. If adopted by all courts, the unified deadlines will be:

• Plaintiffs’ general causation expert disclosures: December 1, 2025
• Defendants’ disclosures: January 9, 2026
• Expert depositions completed: February 20, 2026
• Rule 702 motions filed: March 22, 2026
• Oppositions to Rule 702 motions: April 21, 2026
• Optional replies (if permitted): April 28, 2026

This phase is crucial for determining whether plaintiffs can prove that Depo-Provera’s active ingredient, medroxyprogesterone acetate, can cause meningioma brain tumors.

State Court Coordination

• New York: 78 plaintiffs are now consolidated under Judge Sabrina Kraus. BrownGreer is assisting with threshold reviews.
• Delaware: 332 plaintiffs are involved, though a procedural dispute with the Keller Postman firm remains over threshold proof orders.
• California, Illinois, Pennsylvania, Connecticut, and New Mexico: Cases are active and at varying stages of motion practice and scheduling

Product Use and Injury Documentation

Under PTOs 17, 22, and 22A, plaintiffs continue submitting evidence of Depo-Provera use and meningioma diagnosis through MDL Centrality.

The court-appointed vendor BrownGreer is managing document intake and validating case completeness.

October 14, 2025: Hundreds of Women Plan Lawsuits Over Contraceptive Injection Allegedly Linked to Brain Tumors

Thousands of women have filed claims alleging that the injectable contraceptive Depo-Provera caused them to develop meningiomas, a form of brain tumor.

The lawsuits target Pfizer and other manufacturers, alleging they failed to warn users about known risks tied to long-term use of the hormone-based shot.

A 2024 British Medical Journal study found women using certain high-dose progestogen drugs faced up to a sixfold higher risk of developing these tumors.

While regulators in Europe and Canada have added warnings to Depo-Provera labels, U.S. labels have not yet changed, fueling allegations of negligence and misrepresentation.

Plaintiffs argue the companies prioritized profits over safety and withheld evidence from the public.

October 1, 2025: October 2025 JPML Update

The Depo-Provera lawsuit saw a notable rise in activity between September and October, increasing from 806 cases to 1,222.

This 50%+ increase signals growing awareness of alleged long-term effects linked to the injectable birth control, particularly concerning bone density loss and other serious health complications.

As more claimants come forward, this trend may continue if public exposure and legal advertising persist.

The litigation is still in its early stages, but the sharp month-over-month growth points to heightened momentum.

Our attorneys are actively accepting new clients for the Depo-Provera Lawsuit, helping them gather evidence of their Depo-Provera usage and assess the impact of their brain tumors in financial terms. 

Contact us today for a free consultation, or use the chat feature on this page to find out if you qualify for the Depo-Provera Lawsuit instantly. 

September 26, 2025: Depo-Provera Brain Tumor MDL Expands Ahead of Preemption Showdown

The multidistrict litigation over Pfizer’s contraceptive Depo-Provera now includes more than 1,300 plaintiffs, up from just over 70 in February, as a critical September 29 hearing on federal preemption approaches in the Northern District of Florida.

Plaintiffs allege the drug increases the risk of meningiomas, slow-growing brain tumors, and claim Pfizer failed to warn consumers despite growing scientific evidence, including a recent JAMA Neurology study linking long-term use to a twofold higher risk.

September 24th, 2025: Plaintiffs Challenge Pfizer’s Preemption Defense in Depo Provera Brain Tumor Litigation

Plaintiffs in the Depo Provera brain tumor lawsuit filed a firm opposition to Pfizer’s attempt to dismiss the case based on federal preemption.

The brief argues that Pfizer concealed vital information about meningioma risks from the FDA, minimized epidemiological studies, and disregarded decades of mechanistic evidence.

According to the plaintiffs, Pfizer even disclosed more to foreign regulators than to U.S. officials.

The filing also highlights that the FDA has never rejected a sufficient warning.

Plaintiffs cite a 2024 Complete Response Letter as evidence that stronger warnings were always possible and argue that Pfizer’s subsequent withdrawal of low-dose Depo Provera supports this point.

They argue that a broad reference to meningioma does not fulfill Pfizer’s duty to warn about risks specifically linked to high-dose injectable MPA.

Finally, the opposition claims that Pfizer could have marketed safer options, such as the SubQ formulation, and nothing in federal law prevented it.

Plaintiffs contend this undermines Pfizer’s argument of “impossibility,” which is the critical standard for preemption.

If accepted, the argument preserves the litigation and prevents Pfizer from avoiding liability through preemption.

September 23rd, 2025: Upcoming Case Management Conference and Preemption Hearing 

According to the August 25, 2025 Case Management Order (CMO), the next Case Management Conference is scheduled for Monday, September 29, 2025, at 9:00 a.m. Central Time in the U.S. District Court for the Northern District of Florida.

Oral arguments on preemption will follow the conference.

These proceedings are expected to shape the future of the litigation by addressing whether federal law preempts plaintiffs’ state law failure-to-warn claims: an issue that could influence the outcome of thousands of cases.

Visit this page for further information and news on the Depo Provera Lawsuit as these integral meetings and conferences are completed.

September 22nd, 2025: Depo-Provera Lawsuits Grow Amid Brain Tumor Concerns

Thousands of women across the U.S. are filing lawsuits alleging that Depo-Provera birth control injections caused them to develop intracranial meningioma brain tumors.

As of now, over 10,000 women are pursuing or preparing to file Depo-Provera lawsuits, claiming the manufacturer failed to warn about the 5.5x increased risk of developing meningiomas linked to the hormone medroxyprogesterone acetate, the active ingredient in the long-acting birth control shot.

Many women diagnosed with meningiomas years after receiving Depo-Provera are only now learning about the potential connection.

Others are reporting neurological symptoms such as headaches, vision problems, and dizziness, which they now fear could be signs of an undiagnosed brain tumor.

Recent lawsuits include both individual injury claims and class action complaints demanding medical monitoring for women who used the injection and are concerned about long-term tumor risks.

Depo-Provera has been in use for decades and was widely marketed as a safe, convenient contraceptive option.

Plaintiffs allege that the manufacturer failed to adequately disclose the serious risks associated with the drug and demand accountability for failing to provide sufficient warnings.

Women sharing their experiences have reported lifelong fears and uncertainty about their health due to these alleged risks.

September 9, 2025: New Study Fuels Depo-Provera MDL as Pfizer Faces Preemption Battle Over Meningioma Risks

A new JAMA Neurology study published online September 2, 2025, highlights a biologically plausible connection between female sex hormones and the development and growth of meningiomas—the most common primary brain tumors, which are predominantly benign and occur at a rate of 6 to 8 new cases per 100,000 people annually.

The study highlights that meningiomas have a well-documented sex predilection, with incidence rising after puberty, and more than 60% of these tumors express progesterone receptors.

Moreover, tumor size appears to increase during periods of elevated estradiol and progesterone levels, such as during childbearing years and pregnancy JAMA Network.

These scientific findings sit at the heart of escalating litigation.

In February 2025, litigation over Depo-Provera (DMPA) was centralized in MDL No. 3140 in the Northern District of Florida, where more than 500 cases are now pending.

Plaintiffs, many of whom developed meningiomas and subsequently suffered significant neurological complications (like seizures, vision loss, or cognitive impairment) allege that Pfizer failed to adequately warn users, despite long-standing scientific signals.

Pfizer has moved to dismiss failure-to-warn claims on the grounds of federal preemption, noting that in late 2023, the FDA declined to approve a labeling update regarding meningioma risk.

The company argues this regulatory refusal precludes state-law claims alleging failure to warn Reuters.

Plaintiff attorneys counter that Pfizer had been aware (since at least the 1980s) of growing evidence linking DMPA to meningioma risk and nonetheless failed to protect patients.

To test these competing claims, the court has designated five “pilot” cases to proceed first.

The initial rulings on Pfizer’s preemption argument and the validity of the scientific evidence will likely shape the direction of the broader litigation, influencing both settlement dynamics and whether remaining cases move forward

September 2, 2025: September 2025 JPML Update

The number of Depo-Provera lawsuits awaiting consolidation continues to grow.

In September, 806 cases were centralized in the Depo Provera MDL, compared to 550 in August.

This increase of more than 250 cases in one month highlights the rapid pace at which new claims are being filed.

The pending litigation involves allegations that the birth control injection Depo-Provera caused serious health complications, including bone density loss and breast cancer.

Plaintiffs across the country are seeking consolidation through the Judicial Panel on Multidistrict Litigation (JPML).

Our attorneys are actively accepting new clients for the Depo-Provera Lawsuit, helping them gather evidence of their Depo-Provera usage and assess the impact of their brain tumors in financial terms. 

Contact us today for a free consultation, or use the chat feature on this page to find out if you qualify for the Depo-Provera Lawsuit instantly.

August 25, 2025: Depo-Provera Lawsuits Surpass 960 Filings With Over 9,500 Claims Under Review

Nearly 1,000 Depo-Provera meningioma lawsuits are now pending nationwide, while more than 9,500 additional claims are still under investigation. 

The lawsuits allege that long-term use of Depo-Provera, a hormonal contraceptive injection, increased the risk of meningioma, a brain tumor that can lead to neurological impairment, headaches, and vision loss.

Earlier this year, the Judicial Panel on Multidistrict Litigation (JPML) consolidated Depo-Provera lawsuits into multidistrict litigation (MDL) before U.S. District Judge M. Casey Rodgers in the Northern District of Florida. Multidistrict litigation streamlines pretrial proceedings by centralizing federal claims with common issues, allowing coordinated discovery and early test trials.

Pfizer, the manufacturer of Depo-Provera, is expected to file a motion for summary judgment this month, arguing that federal law preempts the claims.

If the litigation proceeds past the preemption challenge, five bellwether cases will be prepared for early jury trials. 

Bellwether trials provide insight into how juries may respond to evidence and testimony, and the results often shape broader settlement negotiations.

Depo-Provera contains medroxyprogesterone acetate, a synthetic progestin administered every three months as birth control.

The lawsuits reference recent research indicating that women who used Depo-Provera for more than one year faced a more than fivefold increased risk of developing meningioma.

Plaintiffs allege that Pfizer failed to adequately warn about these risks and prioritized sales over patient safety.

August 18th, 2025: Ohio Woman Files Lawsuit After Brain Tumor Allegedly Linked to Depo-Provera Use

An Ohio woman has filed a lawsuit against Pfizer and other manufacturers of Depo-Provera, alleging the birth control shot caused her to develop a debilitating brain tumor requiring lifelong medical monitoring.

The plaintiff began using Depo-Provera in 1994 and received the injections for 10 years.

She was diagnosed with an intracranial meningioma in 2023 after experiencing symptoms such as seizures, balance problems, and persistent headaches.

The lawsuit claims that the manufacturers failed to adequately warn about the risk of brain tumors linked to depot medroxyprogesterone acetate (DMPA), the active ingredient in Depo-Provera.

Shepherd underwent surgery to remove the tumor, but now requires routine MRIs and CT scans to monitor for recurrence and faces long-term psychological distress due to the risk of future neurological damage.

Filed in the Northern District of Florida, Shepherd’s case is part of the growing Depo-Provera brain tumor litigation now consolidated under U.S. District Judge M. Casey Rodgers.

Early “pilot” trials are being prepared to test the strength of the claims before juries.

Plaintiffs argue that the drug’s manufacturers ignored data linking DMPA use to intracranial meningiomas and failed to update warnings despite mounting evidence.

August 5th, 2025: Depo-Provera Brain Tumor Lawsuit Update

A new Depo-Provera lawsuit filed by a Louisiana woman alleges she developed an intracranial meningioma after receiving Depo-Provera injections from 2001 to 2012.

Her symptoms escalated to include full-body numbness on the left side, culminating in invasive brain surgery in 2019

The Plaintiffs case joins over 550 others now centralized in a multidistrict litigation (MDL) before Judge M. Casey Rodgers in the Northern District of Florida.

The lawsuits accuse Pfizer and its affiliated companies of failing to warn patients and doctors about the risks of intracranial meningiomas tied to prolonged exposure to medroxyprogesterone.

Medroxprogesterone is the active ingredient found in the Depo-Provera shot.

Scientific studies have indicated that synthetic progestins like those in Depo-Provera may contribute to tumor growth.

Plaintiffs argue that these dangers were known or should have been known long before recent research brought them to light.

Bellwether trials are now being prepared to assess jury reactions to the core evidence and expert testimony.

These early trials will help shape the future of potential settlements or continued litigation for thousands of women affected.

August 1, 2025: August 2025 JPML Update

The Depo-Provera MDL grew by 115 cases between July and August, bringing the total to 550.

Plaintiffs continue to allege that Pfizer’s injectable contraceptive caused them to suffer serious bone density loss.

The increase reflects steady plaintiff-side activity as more individuals come forward with long-term health concerns tied to the product.

Our attorneys are actively accepting new clients for the Depo-Provera Lawsuit, helping them gather evidence of their Depo-Provera usage and assess the impact of their brain tumors in financial terms. 

Contact us today for a free consultation, or use the chat feature on this page to find out if you qualify for the Depo-Provera Lawsuit instantly. 

July 29th, 2025: Judge Demands Transparency on Unified Depo-Provera Meningioma Lawsuits

The federal judge overseeing the growing number of Depo-Provera brain tumor lawsuits is pressuring plaintiffs’ lawyers to disclose how many cases remain unfiled.

Judge M. Casey Rodgers, who presides over the MDL in the Northern District of Florida, raised concerns that attorneys are delaying the filing of claims until the court rules on key preemption defenses later this year.

As of now, more than 550 lawsuits have been filed by women who developed meningiomas after receiving Depo-Provera, a long-acting birth control injection manufactured by Pfizer and generic drugmakers.

However, plaintiffs have indicated that hundreds (or potentially thousands) more cases are likely to be filed.

The lawsuits claim that Depo-Provera increases the risk of intracranial meningiomas, citing recent studies showing a five-fold increased risk in certain users.

Plaintiffs argue that the drug manufacturers failed to warn women and healthcare providers of this danger.

Judge Rodgers warned that delaying the filing of cases until after a decision on Pfizer’s preemption defense (which argues that federal law barred it from changing the warning label) is disruptive to the litigation process.

She made clear that leadership roles in the MDL could be revoked if firms wait to file en masse after the ruling.

The deadline to certify the number of unfiled claims is July 31, and oral arguments on preemption are scheduled for September 29.

If the claims survive, five bellwether trials will move forward, offering key insights into jury response and influencing possible settlement talks.

July 22, 2025: Depo-Provera Lawsuit Filed Over Meningioma Diagnosis and Brain Surgery After Long-Term Use

A Nebraska woman has filed a product liability lawsuit against Pfizer Inc., alleging that her long-term use of the injectable contraceptive Depo-Provera caused her to develop multiple meningiomas, requiring invasive brain surgeries.

The lawsuit, filed on July 16, 2025, in the U.S. District Court for the Northern District of Florida, joins a growing multidistrict litigation (MDL No. 3140) involving over 500 similar claims.

The plaintiff, Amy Samsel, used Depo-Provera for more than 21 years before being diagnosed with two brain tumors in 2023.

According to the complaint, the tumors led to neurological symptoms including dizziness, vision problems, and papilledema. She underwent two craniotomies to remove the tumors.

Samsel alleges that Pfizer and other defendants failed to warn about the known risk of intracranial meningiomas associated with long-term use of Depo-Provera.

The suit cites scientific research dating back to the 1980s, including a 2024 French study linking prolonged progestin use with a 5.6-fold increased risk of meningioma.

While European and Canadian regulators have added meningioma warnings to Depo-Provera labeling, similar disclosures have not been implemented in the U.S.

Claims in the lawsuit include failure to warn, design defect, negligence, misrepresentation, and breach of warranty.

The case is part of coordinated pretrial proceedings overseen by Judge M. Casey Rodgers, who has scheduled a series of bellwether trials to begin in the coming year.

The outcome of early trial cases may influence the direction of future settlements or rulings in the MDL.

July 16, 2025: Over 550 Depo-Provera Lawsuits Consolidated in MDL Over Brain Tumor Allegations

More than 550 product liability lawsuits have been filed against Pfizer over allegations that its contraceptive injection, Depo-Provera, caused users to develop meningioma brain tumors.

Depo-Provera Lawsuits have been consolidated in federal multidistrict litigation (MDL No. 3140) in the U.S. District Court for the Northern District of Florida under Judge M. Casey Rodgers.

Countless plaintiffs allege they developed serious brain tumors after receiving Depo-Provera injections over extended periods.

Discovery is currently underway, and early bellwether trial selections are expected in late 2025 or early 2026.

Pfizer is expected to challenge the claims through preemption defenses, asserting that federal regulatory approval of Depo-Provera bars state-level failure-to-warn claims. Briefing on these motions is anticipated later this year.

Depo-Provera packaging in the U.S. does not currently include a warning about meningioma risks.

In contrast, regulators in Europe and Canada require such warnings.

Plaintiffs in the MDL generally allege that Pfizer knew or should have known about the risk and failed to adequately inform users and the medical community.

The lawsuits seek compensation for medical expenses, lost wages, and long-term disability associated with brain tumor treatment.

TorHoerman Law is currently reviewing potential claims involving individuals who developed meningioma after receiving Depo-Provera injections.

July 14, 2025: Judge Orders Disclosure of Pre-Settlement Loans in Depo-Provera Lawsuits

On July 9, 2025, U.S. District Judge M. Casey Rodgers issued a pretrial order requiring all plaintiffs involved in the Depo-Provera multidistrict litigation (MDL) to disclose details of any pre-settlement funding arrangements.

The order mandates attorneys to submit documentation identifying the funding company, loan amount, interest rate, fees, and repayment terms.

The court expressed concern that some plaintiffs may have entered into high-interest funding agreements that could influence their settlement decisions.

Judge Rodgers emphasized the need to protect plaintiffs from predatory lending practices that may erode their financial recovery and interfere with the resolution of the litigation.

The disclosure order follows a broader judicial trend of increasing transparency around third-party litigation financing, particularly in mass tort cases where plaintiffs may face financial hardship while awaiting trial or settlement.

The Depo-Provera MDL consolidates claims alleging that the injectable birth control caused irreversible bone density loss and other long-term health effects.

Pretrial proceedings continue as parties engage in coordinated discovery and settlement discussions.

July 3rd, 2025: Depo-Provera Lawsuits Allege Brain Tumor Risks from Long-Term Use

Pfizer is currently facing a growing wave of litigation in both the U.S. and U.K. from hundreds of women who claim that long-term use of Depo-Provera caused them to develop meningiomas—noncancerous but potentially dangerous brain tumors.

The lawsuits were filed following a 2024 British Medical Journal study that linked progestogens, the hormone used in Depo-Provera, to a significantly increased risk of meningiomas.

The study found that women using the injection for over a year had a 5.6 times greater likelihood of developing the tumors.

A separate 2024 study published by the National Library of Medicine supported these findings.

Despite these emerging concerns, Depo-Provera’s official U.S. label still does not mention meningioma risks as of mid-2025.

Plaintiffs allege Pfizer was aware of these dangers but failed to warn consumers or update safety information in the U.S., even though similar warnings were issued in other countries.

Depo-Provera is approved to prevent pregnancy for three months per injection and is not recommended for use beyond two years.

Plaintiffs argue that Pfizer failed to communicate safer alternatives or adequately update risk disclosures, potentially exposing millions of women to long-term harm.

July 1st, 2025: July 2025 JPML Update

The Depo-Provera MDL rose to 435 cases by July 1st, up from 348 in June.

This is the largest monthly increase reported since tracking began.

Plaintiffs allege that the birth control injection caused bone density loss and other long-term health complications.

The litigation is still in early procedural stages, with coordination focused on consolidating claims and case management.

Our attorneys are actively accepting new clients for the Depo-Provera Lawsuit, helping them gather evidence of their Depo-Provera usage and assess the impact of their brain tumors in financial terms. 

Contact us today for a free consultation, or use the chat feature on this page to find out if you qualify for the Depo-Provera Lawsuit instantly.

June 16th, 2025: Generic Defendants Likely to Be Dismissed as Brand Cases Advance

On June 11, U.S. District Judge M. Casey Rodgers, who is presiding over the federal multidistrict litigation (MDL) regarding Depo-Provera birth control shots, issued a case management order.

This order suggests that the authorized generic manufacturers Greenstone, Viatris, and Prasco will likely be excluded from the litigation soon.

During a case management conference on May 30, plaintiffs’ attorneys suggested that these companies are expected to be released, awaiting further assessment of their role related to the drug.

The MDL now encompasses over 400 Depo-Provera Lawsuits, centering on claims that these birth control injections contributed to the development of meningioma brain tumors, with Pfizer and other brand-name manufacturers purportedly failing to disclose this risk.

Since March 2025, over 300 lawsuits have been consolidated.

Discovery is ongoing, as the deadlines for producing documents related to preemption and general causation have passed since May 11.

Judge Rodgers stated that bellwether trials are slated to begin in late 2026 or early 2027 to assess key arguments and support possible settlements.

June 12, 2025: Pfizer Seeks Dismissal of Depo-Provera Brain Tumor Lawsuits on Preemption Grounds

On September 29, 2025, U.S. District Judge M. Casey Rodgers will hear oral arguments on Pfizer’s motion to dismiss over 400 lawsuits filed in the Depo-Provera brain tumor multidistrict litigation.

The motion centers on federal preemption, a legal doctrine that could block the cases from proceeding to discovery.

Pfizer argues that it cannot be sued under state failure-to-warn laws because the U.S. Food and Drug Administration previously rejected a proposed warning about brain tumor risks for Depo-Provera.

The company contends that federal law preempts any state law claims requiring a warning the FDA declined to approve.

Plaintiffs argue that Pfizer has not met the high burden required to invoke preemption and maintain that the FDA’s denial did not amount to a categorical prohibition on additional warnings.

They assert that drug manufacturers can still be held liable under state law when new evidence of risk emerges. Plaintiffs cite recent studies linking Depo-Provera to increased risks of brain tumors as justification for their claims.

The court’s decision could determine whether the federal litigation moves forward into discovery or is dismissed at the threshold. A ruling is expected in October.

June 5th, 2025: Pfizer Advocates for Mass Tort Program in Pennsylvania Depo-Provera Litigation

Pfizer has requested that the Philadelphia Court of Common Pleas establish a mass tort program for lawsuits concerning Depo-Provera brain tumors.

Although only two lawsuits have been filed in Philadelphia so far, one involves over 100 plaintiffs.

Nearly all the plaintiffs had their claims severed and dismissed without prejudice on May 30, allowing them to refile individually.

Pfizer expects a surge in new filings and argues that centralizing the cases will streamline the litigation process.

Attorneys anticipate that the court’s decision on whether to approve the mass tort program could greatly affect how the Pennsylvania docket proceeds.

TorHoerman Law associate attorney Alexis Robinson has provided an update on the progress of the Depo-Provera Lawsuits.

Judge Casey Rogers has been assigned to oversee the litigation and has set regular status conferences through 2025 to keep the case on track.

She recently issued an order to show cause against the manufacturers, Greenstone and Biatric, for missing court-imposed deadlines.

In addition, she selected five early cases to proceed as bellwether trials, a significant step that can help determine how the larger pool of cases may be resolved.

Judge Rogers has also implemented a streamlined process for obtaining medical records and issuing subpoenas to medical providers and pharmacies.

Her prior experience managing large-scale mass torts is expected to support an efficient and organized path forward in the Depo-Provera Lawsuit proceedings.

Her active management may help accelerate progress toward resolution.

The court’s increasing activity makes it important for potential claimants to act quickly, as the time to join the litigation may be limited.

Individuals who believe they may qualify should start the process by completing the online chat feature evaluation on our website.

Current clients should ensure they complete the onboarding process in full to avoid missing deadlines that could impact their claims.

As with all complex litigation, timelines and procedures may shift as the case evolves.

The information provided here reflects current expectations and should be viewed as a general update rather than a guarantee of outcome or timing.

June 2nd, 2025: June 2025 JPML Update

The Depo-Provera MDL grew by an additional 59 new cases between May and June, bringing the total to 348.

Lawyers are reviewing medical histories and expert reports as preliminary discovery efforts begin to shape the core claims in the litigation.

Our attorneys are actively accepting new clients for the Depo-Provera Lawsuit, helping them gather evidence of their Depo-Provera usage and assess the impact of their brain tumors in financial terms. 

Contact us today for a free consultation, or use the chat feature on this page to find out if you qualify for the Depo-Provera Lawsuit instantly. 

May 27, 2025: Lower-Dose Depo-SubQ Provera 104 Could Factor Heavily in Brain Tumor Lawsuits

As litigation over alleged brain tumor risks tied to Depo-Provera continues to grow, attention is turning to a lower-dose alternative that some experts say may have posed fewer risks to long-term users.

Depo Sub-Q Provera 104, a formulation developed by Pfizer, delivers 104 mg of medroxyprogesterone acetate via subcutaneous injection.

That’s significantly less than the 150 mg dose delivered intramuscularly in the traditional Depo-Provera shot.

Medical experts suggest the lower dose could have substantially reduced the risk of meningioma, which are non-cancerous brain tumors linked to long-term use of synthetic hormones.

They believe this is because a lower dose would lead to less hormone buildup in the body over time.

Despite this potential safety benefit, Pfizer made limited efforts to transition patients to the lower-dose version, according to attorneys representing plaintiffs in the Depo-Provera multidistrict litigation (MDL).

Lawyers argue the decision to continue promoting the higher-dose product was driven more by market considerations than medical ones.

May 19th, 2025: New Study Links Long-Term Depo-Provera Use to Tripled Risk of Brain Tumors, Fueling MDL Claims Against Pfizer

A new peer-reviewed study published in February 2025 has added significant weight to the growing body of evidence linking Depo-Provera to brain tumors.

Researchers from the University of British Columbia conducted a large-scale nested case-control study comparing users of Depo-Provera to users of a common oral contraceptive (ethinylestradiol-levonorgestrel).

Their analysis, based on U.S. insurance claims data, found that women who used Depo-Provera for more than one year were 3.5 times more likely to develop meningioma than those on oral contraceptives.

The researchers used rigorous methods to account for disease latency and other confounding factors, addressing concerns raised by earlier studies that lacked active comparators or control for the timing of tumor development.

Notably, the risk remained elevated even after longer use, with adjusted incidence rate ratios of 2.95, 3.17, and 3.50 for two, three, and four years of use, respectively.

The study underscores a possible biological mechanism for the risk, as meningiomas frequently overexpress progesterone receptors—the same receptors targeted by Depo-Provera to prevent pregnancy.

Although the European Medicines Agency has recommended adding meningioma warnings to Depo-Provera’s label, the U.S. FDA has not yet followed suit.

Plaintiffs in the Depo-Provera multidistrict litigation (MDL) have cited emerging studies like this one to argue that Pfizer failed to adequately warn women about long-term tumor risks.

With over a million prescriptions filled annually, the findings are expected to play a key role in both ongoing discovery and potential bellwether trials in the Depo-Provera brain tumor MDL.

May 1st, 2025: May 2025 JPML Update

159 cases have been added to the Depo-Provera MDL in the past month, the largest influx of cases since the MDL was established.

As more individuals become aware of the links between Depo-Provera and brain tumors, the number of lawsuits continues to increase.

The federal lawsuit for Depo-Provera brain tumors is progressing quickly, with the MDL judge ironing out which defendants will remain named in the lawsuit and which are dismissed.

The MDL judge is implementing strict deadlines for defendants and has ruled that early depositions will not be necessary at this stage of the litigation.

April 22nd, 2025: Judge Presses Forward in Depo-Provera MDL as Generic Makers Face Scrutiny

The Depo-Provera Lawsuit is ongoing. 

The Depo-Provera brain tumor multidistrict litigation (MDL) is progressing, with U.S. District Judge M. Casey Rodgers issuing decisive rulings aimed at maintaining efficiency and transparency.

In recent weeks, the judge accepted affidavits from generic drug manufacturers Greenstone, Viatris, and Prasco, addressing their alleged involvement with the birth control shot linked to brain tumors such as meningiomas.

Prasco submitted its affidavit on time, while Greenstone and Viatris initially failed to comply—prompting an Order to Show Cause.

However, the court has since confirmed receipt of all affidavits and ruled that early depositions will not be necessary at this stage.

This streamlines the discovery process without waiving plaintiffs’ rights to challenge the generics’ role later in litigation.

Plaintiffs’ attorneys are close to reaching a stipulation that may result in Prasco’s dismissal from the MDL.

Greenstone and Viatris, however, remain active defendants and are expected to fully comply with upcoming discovery obligations regarding product distribution and liability.

Judge Rodgers’ active case management has ensured steady progress in a rapidly growing MDL, which now includes thousands of women alleging they developed brain tumors after receiving Depo-Provera injections.

The court’s insistence on strict deadlines sends a strong message that delays and noncompliance will not be tolerated.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

The federal judge overseeing all Depo-Provera brain tumor lawsuits has scheduled monthly case management conferences through 2025, aimed at keeping the litigation on track for early bellwether trials.

These lawsuits, centralized in a multidistrict litigation (MDL) before U.S. District Judge M. Casey Rodgers in the Northern District of Florida, involve claims that Pfizer and other manufacturers failed to warn about the risk of meningioma brain tumors linked to long-term use of the birth control injection.

As of now, at least 130 cases have been filed, though that number is expected to grow significantly.

In a proactive move, Judge Rodgers independently selected five pilot cases for early trials and is pushing both sides to make consistent progress.

The next status conference is scheduled for May 30.

While early trials may not begin until late 2026 or early 2027, their outcomes are expected to shape future settlement negotiations and influence the direction of thousands of similar claims.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

The Depo-Provera Lawsuit is ongoing. 

U.S. District Judge M. Casey Rodgers is holding parties accountable in the Depo-Provera brain tumor MDL, recently issuing an order to Show Cause after generic manufacturers Greenstone and Viatris missed a court deadline.

The defendants were given fourteen days under Case Management order No. 2 to submit the documentation to file a Notice of Compliance.

While Prasco met the deadline, Greenstone and Viatris did not.

This type of court order, which demands an explanation for failure to follow judicial instructions, can carry serious consequences.

Although both later submitted required affidavits confirming non-involvement with the drug, the judge warned that future delays will not be tolerated.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

The Depo-Provera Lawsuit is ongoing. 

A recent court order in the Depo-Provera multidistrict litigation (MDL) has established a formal procedure for plaintiffs to verify their medication use.

According to this ruling, plaintiffs must submit a “Plaintiff Proof of Use/Injury Questionnaire” within 120 days of March 14, 2025, or within 120 days of filing for newly added cases.

To aid in this process, the court has approved a method for obtaining third-party records to confirm whether individuals received Depo-Provera or its generic alternative, DMPA.

Since many plaintiffs may have received the injection years ago, accessing conventional medical records can be challenging.

The court order requires that third-party organizations, including pharmacies, healthcare providers, insurers, and military medical institutions, produce documents that may assist in verifying usage.

This documentation could include purchase histories, shipping logs, or insurance payment data that indicate a facility’s administration of Depo-Provera or a similar medication.

To simplify the retrieval of these records, the court has authorized plaintiffs to use a standardized HIPAA and HITECH-compliant release form and a medical provider identification form.

If a provider does not voluntarily comply with a request, plaintiffs’ legal teams can issue subpoenas without encountering additional procedural barriers.

Additionally, the order mandates that third-party entities comply with these subpoenas or requests without imposing unnecessary administrative burdens.

Restrictions such as proprietary forms, original signatures, or excessive processing fees that might obstruct access to records are prohibited.

This court directive represents a significant advancement in enabling plaintiffs to obtain crucial documentation to support their cases.

By offering a structured and enforceable method, it seeks to reduce challenges related to incomplete or inaccessible medical records, thus enhancing efficiency in the litigation process.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

A recent court order in the Depo-Provera multidistrict litigation (MDL) has established a formal procedure for plaintiffs to verify their medication use.

According to this ruling, plaintiffs must submit a “Plaintiff Proof of Use/Injury Questionnaire” within 120 days of March 14, 2025, or within 120 days of filing for newly added cases.

To aid in this process, the court has approved a method for obtaining third-party records to confirm whether individuals received Depo-Provera or its generic alternative, DMPA.

Since many plaintiffs may have received the injection years ago, accessing conventional medical records can be challenging.

The court order requires that third-party organizations, including pharmacies, healthcare providers, insurers, and military medical institutions, produce documents that may assist in verifying usage.

This documentation could include purchase histories, shipping logs, or insurance payment data that indicate a facility’s administration of Depo-Provera or a similar medication.

To simplify the retrieval of these records, the court has authorized plaintiffs to use a standardized HIPAA and HITECH-compliant release form and a medical provider identification form.

If a provider does not voluntarily comply with a request, plaintiffs’ legal teams can issue subpoenas without encountering additional procedural barriers.

Additionally, the order mandates that third-party entities comply with these subpoenas or requests without imposing unnecessary administrative burdens.

Restrictions such as proprietary forms, original signatures, or excessive processing fees that might obstruct access to records are prohibited.

This court directive represents a significant advancement in enabling plaintiffs to obtain crucial documentation to support their cases.

By offering a structured and enforceable method, it seeks to reduce challenges related to incomplete or inaccessible medical records, thus enhancing efficiency in the litigation process.

Additionally, the Depo-Provera Lawsuit experienced a significant increase in new filings between March and April 2025.

Between February and March, the litigation saw 78 new cases filed.

By April 1st, the number of Depo-Provera Lawsuits pending surged to 130, an increase of 52 new cases.

This notable rise in filings reflects growing attention to the potential risks associated with Depo-Provera, particularly in relation to claims of brain tumor risk linked to its use.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

March 18th, 2025: Depo-Provera Lawsuits Move Forward with Direct Filing in MDL

The Depo-Provera Lawsuit is ongoing. 

The U.S. District Judge overseeing Depo-Provera brain tumor lawsuits has authorized direct filing in the multidistrict litigation (MDL), streamlining the process as more women file claims against the birth control shot’s manufacturer.

Judge M. Casey Rodgers, presiding in the Northern District of Florida, issued a case management order allowing plaintiffs to file directly in the MDL, avoiding delays from transferring cases between courts.

The litigation centers on allegations that Depo-Provera increases the risk of meningioma, a type of benign brain tumor, and that manufacturers failed to warn women and doctors.

Unlike typical mass tort cases, the MDL will not require a master complaint, short-form complaints, or a Science Day, as the court deemed them unnecessary.

Judge Rodgers has also appointed 63 attorneys to leadership roles, including those overseeing discovery, expert testimony, and trial preparation.

The litigation is expected to grow rapidly, with five pilot cases selected for early bellwether trials.

The MDL webpage is now live for case updates, and the next status conference date is pending.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

The Depo-Provera Multidistrict Litigation (MDL) is Progressing. 

The Depo-Provera multidistrict litigation (MDL) is progressing under Judge Rodgers, with both sides finalizing a structured case management plan.

Plaintiffs can now file cases directly into the MDL, expediting the process by which individuals can file Depo-Provera Lawsuits.

A pilot case schedule is in place, setting deadlines for amended complaints, discovery, expert disclosures, and dispositive motions.

A central dispute remains: whether expert testimony is necessary on preemption.

Plaintiffs argue it is, while Defendants seek early dismissal based on legal grounds.

Key agreements include confidentiality protections, proof of Depo-Provera use and injury, and Pfizer’s document production requirements.

Plaintiffs secured 35 deposition days for Pfizer witnesses, plus additional time for other Defendants, with remote and video depositions permitted.

Generic distributors Greenstone and Prasco may be dismissed in cases where Plaintiffs didn’t use their products.

Special Master David Herndon and CPA Randall Sansom will oversee case management and attorney compensation.

Both sides agreed that a Science Day is unnecessary for now, keeping medical monitoring class actions on hold.

Discovery is now underway, and more developments are expected in the coming months.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

The Depo-Provera Lawsuit is ongoing. 

A new case report warns that Depo-Provera birth control shots may increase the risk of severe blood clots, following a 21-year-old woman’s multiple pulmonary embolisms shortly after receiving the injection.

Doctors at Cape Fear Valley Medical Center documented the case in the journal Cureus, describing how the patient developed phlegmasia cerulea dolens (PCD), a rare and life-threatening form of deep vein thrombosis (DVT).

She required extensive medical intervention, including thrombectomy and anticoagulation therapy.

This follows a recent JAMA study linking Depo-Provera to the highest risk of serious blood clots among hormonal contraceptives.

Meanwhile, Depo-Provera Lawsuits over brain tumors are rapidly increasing, with about 70 cases consolidated in multidistrict litigation (MDL) in Florida.

More claims are expected as women diagnosed with intracranial meningiomas connect their condition to the long-term use of the contraceptive.

The court is preparing for bellwether trials to help determine how juries will respond to evidence.

If settlements are not reached, each case may proceed to trial individually.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

The U.S. District Judge overseeing the federal Depo-Provera Lawsuit, Judge Casey Rodgers, has called for female attorneys to apply for leadership roles within the multidistrict litigation (MDL).

The MDL was established after studies linked Depo-Provera, a popular birth control shot, to an increased risk of brain tumors, particularly meningiomas.

Given that all plaintiffs in the case are women, Judge Rodgers emphasized the need for adequate female representation in the leadership team.

She stated that while not every position must be filled by a female attorney, it is important that women are properly represented.

The deadline for attorney applications is March 7, 2025, with selected lawyers responsible for handling discovery, managing evidence, and advocating on behalf of all plaintiffs in the MDL.

These cases will not be binding for others in the litigation but are expected to influence settlement discussions, as they will provide valuable insights into how juries may respond to similar claims in the future.

This call for female leadership comes amid backlash from a conservative judicial group, the “Article III Project,” which filed a complaint accusing Judge Rodgers of putting gender above merit.

Despite the complaint, Depo-Provera injury lawyers have strongly criticized the group’s actions, affirming that the focus on gender diversity is crucial to ensure fair representation of the plaintiff group, which consists entirely of women or their families.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

The Depo-Provera Lawsuit is ongoing. 

The first status conference in the Depo-Provera multidistrict litigation (MDL) is scheduled for Friday, February 21.

A status conference is an initial court meeting where the judge, attorneys, and involved parties discuss case management, procedural timelines, and next steps.

This allows the court to establish deadlines, address preliminary legal issues, and coordinate discovery efforts before moving forward with litigation.

As the case progresses, this conference will help determine the pace and structure of the lawsuits filed against Depo-Provera’s manufacturers.

More updates to follow as proceedings continue.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

Depo Provera MDL Assigned to Judge Rodgers

The Depo Provera MDL has been officially formed and assigned to Judge Rodgers in the Northern District of Florida.

This decision came as a surprise, as plaintiffs sought California and defendants preferred New York, but the JPML panel ultimately selected the Northern District of Florida, citing Judge Rodgers’ mass tort experience.

Judge Rodgers is well known for overseeing the 3M earplug litigation, and with that case winding down, she now takes on another high-profile mass tort that could span the next five years.

While plaintiffs didn’t get their preferred venue, they are optimistic about Rodgers’ ability to efficiently move the litigation toward bellwether trials and resolution.

This decision marks a turning point in the Depo-Provera litigation.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

The Judicial Panel on Multidistrict Litigation (JPML) held a hearing in Miami, Florida, on January 30, 2025, to discuss consolidating the Depo-Provera cases into a multidistrict litigation (MDL).

While the panel agreed to create an MDL, there was no decision on where to centralize the cases.

At the hearing, the plaintiffs’ attorneys argued that California is the best location, noting that most Depo-Provera lawsuits are already filed there.

They also pointed out that California law allows lawsuits against brand-name drug manufacturers, even when plaintiffs take a generic drug version.

Many of the affected women have undergone brain surgery and could have difficulty traveling, making California a more accessible choice if the case were to go to trial.

Pfizer, the manufacturer of Depo-Provera, wants the litigation to be based in New York, where the company is headquartered.

The company argues that key witnesses and evidence exist and that the lawsuits are spread across multiple states, not just California.

A ruling is expected in the coming weeks.

Attorneys for generic drug manufacturers suggested that filing many early cases in California may have been a legal strategy to influence the location of the MDL.

Once the JPML finalizes a venue, all federal lawsuits related to Depo-Provera will be transferred to that district for pretrial proceedings.

The MDL, designed to streamline the process, promises both sides a more efficient and expedited legal journey, providing reassurance amidst the case’s complexity.

The JPML’s impending decision will be a pivotal factor in shaping the next steps for this ongoing litigation.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit across the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

JPML Consolidation Hearing Set for Jan 30 

The U.S. Judicial Panel on Multidistrict Litigation (JPML) is set to hear arguments on January 30, 2025, about consolidating federal lawsuits related to Depo-Provera into a single multidistrict litigation (MDL). 

These cases, filed against Pfizer and other manufacturers of the birth control shot, claim that the product increases the risk of developing intracranial meningiomas—potentially life-threatening brain tumors.

If approved, the MDL will centralize all current and future lawsuits before one judge to streamline pretrial processes, discovery, and potential early test trials.

Pfizer and generic drug manufacturers have acknowledged the need for an MDL, though they disagree on the appropriate venue for consolidating cases.

The MDL will allow for coordinated pretrial proceedings, but each lawsuit will remain an individual claim.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit in the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

Depo Provera Class Action Filed for Medical Monitoring

Patricia Bonilla filed a new class action lawsuit in the U.S. District Court for the Western District of Pennsylvania on January 17.

The lawsuit seeks medical monitoring for women in multiple states who received at least a year of Depo-Provera injections.

Bonilla claims these women face an increased risk of developing brain tumors and should be eligible for ongoing diagnostic testing, such as MRIs and CT scans.

The suit also calls for establishing a nationwide class or state-specific subclasses to address these claims.

Introduced in 1992, Depo-Provera is used by over 70 million women in the U.S.

While Bonilla has not been diagnosed with a brain tumor, she alleges that her use of Depo-Provera over 11 years has created a need for lifelong monitoring.

This medical monitoring lawsuit is separate from the growing number of individual injury claims filed by women who have already developed meningiomas, requiring surgical intervention and facing severe health consequences.

Plaintiffs argue that drug makers withheld crucial information about the risks despite evidence suggesting a potential link between Depo-Provera and brain tumors.

As the legal battle unfolds, the central issue remains whether manufacturers knew of the risks associated with Depo-Provera and failed to provide adequate warnings, leaving thousands of women to bear the potential health and financial consequences.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit in the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

The growing number of lawsuits alleging a link between Depo Provera and meningioma brain tumors is poised for consolidation under multidistrict litigation (MDL).

The U.S. Judicial Panel on Multidistrict Litigation (JPML) has scheduled a pivotal hearing on January 30, 2025, at the Wilkie D. Ferguson, Jr. U.S. Courthouse in Miami, Florida.

This hearing will determine whether these cases will be consolidated into an MDL, a decision that could significantly shape the litigation’s trajectory.

The location of the MDL, whether in New York or California, is a pivotal factor due to the issue of Innovator’s liability, which affects the rights of the plaintiffs.

Innovator’s liability in product liability law holds a manufacturer or developer responsible for injuries caused by a product, even if it is a new or unapproved design, due to their role in creating and bringing the product to market.

The plaintiffs advocate for the cases to be consolidated in California, where innovator liability laws allow individuals who used generic versions of Depo Provera to pursue legal action against Pfizer.

Notably, 18 of the 22 original MDL motion lawsuits were filed in California.

Conversely, Pfizer is lobbying for the MDL to be located in its home state of New York, where Innovator’s liability does not apply.

Individuals who used generic versions of Depo Provera would likely be barred from participating in the lawsuits if placed in New York.

MDL is the most effective approach for handling complex pharmaceutical cases involving many plaintiffs with diverse injuries.

Unlike a class action lawsuit, MDL centralizes cases for pre-trial proceedings under one federal judge while preserving the individual nature of each claim.

This structure is particularly well-suited to the Depo Provera litigation, as injuries like meningiomas linked to high-dose progestin require individualized evaluations of damages and circumstances.

Once the MDL is established, a streamlined process will allow plaintiffs to file short-form complaints tied to a master complaint.

This will simplify the filing process for attorneys and make it easier for new plaintiffs to join the litigation.

From there, cases are expected to progress toward resolution through individual settlements or a global settlement agreement.

A global settlement plan may include the creation of a compensation fund to address claims collectively.

A settlement matrix would determine payouts, considering each plaintiff’s unique circumstances and injuries, ensuring a fair and equitable process.

This framework is designed to provide efficiency and fairness for victims seeking justice and compensation, instilling confidence as the litigation progresses.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit in the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

Alongside legal efforts in the United States, Depo-Provera Lawsuits are also being pursued in Australia by women who’ve developed brain tumors after extended use of the contraceptive injection.

A growing class action lawsuit is being pursued against Pfizer, the maker of Depo-Provera, after more Australian women are coming forward with complaints of side effects from using the drug, claiming that they were not informed of the risk.

The British Medical Journal (BMJ) study found that women who used Depo-Provera for more than a year had a five-to-six-fold increased risk of developing meningiomas compared to those who did not use the drug.

This revelation has prompted legal action in several countries, including Australia, where the drug has been used for decades.

Law firms in Australia are recruiting participants for a class action lawsuit against Pfizer, claiming the pharmaceutical giant failed to adequately warn users about the serious risks of brain tumors linked to Depo-Provera.

The class action involves Australian women who received Depo-Provera prescriptions between 1992 and the present, during which time the drug was dispensed more than 3.5 million times across the country.

These women argue that their healthcare providers never informed them about the potential dangers of long-term use of the contraceptive.

Many women reported being prescribed the drug for over a decade, while the medical guidelines recommend a maximum of using the drug for two years.

Australian lawyers and legal professionals in the United States alike are investigating whether Pfizer failed to disclose these risks, leaving millions of women unaware of the potential dangers they were facing.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are accepting new clients for the Depo-Provera Lawsuit in the United States. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

The Depo-Provera lawsuit is ongoing. 

Plaintiffs in the Depo-Provera lawsuits have filed a motion with the Judicial Panel on Multidistrict Litigation (JPML) to consolidate the cases into a single multidistrict litigation (MDL).

With 22 cases currently pending, plaintiffs have proposed the U.S. District Court for the Northern District of California as the venue, citing its experience with major MDLs like Roundup.

The next hearing on this matter is scheduled for December 5, 2024, meaning this litigation will not appear on the JPML docket until 2025.

If approved, this could become the first mass tort of the new year.

Plaintiffs argue that the centralized pretrial proceedings provided by an MDL are essential for the complex Depo-Provera litigation, which involves claims of severe health issues such as meningiomas caused by prolonged use of the contraceptive shot.

However, defendants are expected to challenge the consolidation and may seek to move the cases to a District Court in New York instead.

If you have used the Depo-Provera birth control shot and have suffered brain tumors or other serious health complications, you may be eligible to file a Depo-Provera Lawsuit.

Contact the experienced lawyers at TorHoerman Law for a free consultation.

You can also use the chatbot on this page to get in touch with our experienced team instantly by completing a free case evaluation.

Motion Filed to Consolidate Depo-Provera Lawsuits into MDL

On November 26, a motion was filed with the U.S. Judicial Panel on Multidistrict Litigation (JPML) to consolidate at least 22 lawsuits currently pending across eight district courts nationwide.

The proposed multidistrict litigation (MDL) would be centralized in the Northern District of California, where six of the cases have already been filed.

Additionally, plaintiffs anticipate significant growth in the litigation, with many more claims expected to be filed in the coming months.

If the JPML approves the motion, all current and future Depo-Provera lawsuits will be assigned to a single judge for coordinated pretrial proceedings, including discovery and motion hearings.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are still accepting new clients. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

Recent studies reveal that certain brain tumors associated with Depo-Provera use are inoperable due to their location or their involvement with critical brain structures.

As a result, affected women may need alternative treatments such as radiation therapy, hormone therapy, or participation in clinical trials.

The inability to surgically remove these tumors highlights the serious risks of Depo-Provera use and emphasizes the importance of thorough preoperative imaging to evaluate and plan potential treatment options.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are still accepting new clients. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

Lawsuits allege that Depo-Provera, a prescription contraceptive drug manufactured by the defendants, caused severe injuries, and scientific studies have linked medroxyprogesterone acetate (MPA), the active ingredient in Depo-Provera, to meningiomas.

A database analysis revealed that injectable MPA increased the likelihood of developing meningiomas by 53%, with the risk escalating with prolonged use.

Additionally, trends in meningioma incidence between 2004 and 2015 indicate significant increases, particularly among females, African Americans, and younger individuals.

Plaintiffs claim the defendants had knowledge for decades but failed to warn patients and healthcare providers in the U.S. of this significant risk.

Unlike in the U.S., the European and Canadian labels for Depo-Provera now include warnings about the potential for meningiomas.

Some Warnings associated with Depo-Provera include:

• Bone Mineral Density Loss: Long-term use (over two years) may cause irreversible bone loss, especially in adolescents and high-risk individuals.
• Thrombosis: Users experiencing thrombosis should discontinue the drug, with further evaluation needed for vision or neurological issues.
• Cancer Risks: Increased risk of breast and cervical cancers has been observed in some users, particularly those with a family history of breast cancer.
• Ectopic Pregnancy: Severe abdominal pain or suspected pregnancy should prompt evaluation for ectopic pregnancy.
• Adverse Reactions: Includes anaphylaxis, weight gain, depression, and irregular bleeding.

If you have used the Depo-Provera birth control shot and have suffered brain tumors or other serious health complications, you may be eligible to file a Depo-Provera Lawsuit.

Contact the experienced lawyers at TorHoerman Law for a free consultation.

You can also use the chatbot on this page to get in touch with our experienced team instantly by completing a free case evaluation.

A 2024 study provides critical support for Depo-Provera lawsuits.

The study found that discontinuing progesterone drugs like Depo-Provera can lead to the regression of meningioma tumors.

This evidence helps causation claims and supports the argument that Depo-Provera increases the risk of meningiomas and that it directly causes tumors in specific plaintiffs.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are still accepting new clients. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

For nearly a decade, women in Canada who used Depo-Provera and other DMPA medications have been warned about the potential link between these drugs and meningiomas.

Since at least 2016, Pfizer has included a warning in Canada stating that prolonged use of Depo-Provera may increase the risk of developing intracranial meningiomas.

The Canadian product monograph for Depo-Provera explicitly warns: “Meningiomas have been reported following long-term administration of progestins, including medroxyprogesterone acetate (MPA).”

Additionally, the accompanying drug information advises physicians to exercise caution when prescribing Depo-Provera to patients with a history of meningiomas and to discontinue its use immediately if a patient develops a meningioma.

In contrast, Pfizer has not included similar warnings or guidance about meningiomas in the prescribing information for Depo-Provera in the United States.

As a result, many U.S. women are only now becoming aware of the potential association between Depo-Provera and brain tumors.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are still accepting new clients. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

Depo-Provera Settlements and Awards Could Reach High Amounts

Settlements in Depo-Provera lawsuits have the potential to be significantly higher than those seen in comparable mass tort cases. Several factors contribute to this outlook.

A study indicates a 5.5x increase in the risk of brain tumors (meningiomas) among Depo-Provera users.

This is one of the highest relative risk increases documented in large-scale litigation.

Brain tumors are life-altering and dramatic injuries, which often lead to higher settlement values due to their profound impact on plaintiffs’ lives.

According to CDC data:

From 2017 to 2019, about 2% of women aged 15 to 49 used Depo-Provera.

Usage was higher in previous decades: 4.5% of women aged 15 to 44 had used it by 1995, and 23% between 2006 and 2010.

Estimates suggest that several million women used the drug annually during its peak years.

This means approximately 1,300 meningioma cases per year, with the drug being in use for over 32 years.

Overall, between 5,000 and 30,000 potential lawsuits could arise. 

However, not all eligible plaintiffs may choose to file claims, which could further enhance settlement values.

Given the strength of the evidence, severity of injuries, and manageable plaintiff numbers, average settlements are expected to exceed $100,000 per case, with some plaintiffs receiving significantly higher amounts depending on the circumstances.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are still accepting new clients. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

A California woman, Anjanna Lawson, has filed a lawsuit against Pfizer and other associated companies after being diagnosed with an intracranial meningioma.

Lawson began using Depo-Provera injections at the age of 16 and continued until September 2024.

In July 2023, she underwent a right pterional craniotomy to remove the tumor. However, a residual tumor was detected in early 2024, requiring five sessions of stereotactic radiosurgery.

Despite these treatments, the tumor persists, leaving Lawson with debilitating symptoms, including vision loss, facial spasms, and a burning sensation in her face.

The lawsuit targets Pfizer, Inc., Viatris, Inc., Greenstone, LLC, Prasco, LLC, Pharmacia & Upjohn LLC, and Pharmacia, LLC. Lawson alleges that these companies failed to provide sufficient warnings about the risk of developing intracranial meningiomas associated with Depo-Provera use.

Key Details of Anjanna Lawson’s Case:

• Plaintiff: Anjanna Lawson, California resident.
• Defendants: Pfizer, Inc., Viatris, Inc., Greenstone, LLC, Prasco, LLC, Pharmacia & Upjohn LLC, and Pharmacia, LLC.
• Allegations: Failure to warn users about the risks of intracranial meningiomas linked to Depo-Provera.
• Symptoms: Vision loss, facial spasms, and facial burning sensation due to an unresolved tumor.
• Treatment: Right pterional craniotomy followed by stereotactic radiosurgery.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are still accepting new clients. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

Depo-Provera Lawsuits continue to be filed in federal courts, with expectations of more than 30 cases by the end of November.

Filings are particularly concentrated in the Northern District of California and the Southern District of Texas.

The upcoming Judicial Panel on Multidistrict Litigation (JPML) hearing, scheduled for December 5, 2024, will likely address potential consolidation. 

However, an official multidistrict litigation (MDL) is not anticipated before the end of the year.

An MDL is typically created when 25 or more related cases are pending in various federal courts, addressing common issues and involving similar defendants.

This threshold is expected to be met in the Depo-Provera lawsuits.

Although plaintiffs are likely to seek consolidation in California, defendants may oppose and recommend New York as the venue for coordination.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are still accepting new clients. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to find out if you qualify for a claim instantly. 

A new lawsuit against the makers of Depo-Provera has been filed in the U.S. District Court for the Central District of California, alleging that the popular birth control shot led to the development of a meningioma brain tumor in a California woman after nearly 25 years of use.

The plaintiff is suing Pfizer, Viatris, Greenstone, Prasco, and Pharmacia and Upjohn, asserting that the companies failed to provide adequate warnings in the U.S. about the potential risk of brain tumors linked to Depo-Provera, a risk noted on Canadian labels since 2015.

The lawsuit claims that Jones began receiving Depo-Provera injections in 2000, with regular injections totaling 91 over her treatment period.

In 2020, after experiencing symptoms like headaches, blurred vision, vertigo, and ear itching, she was diagnosed with a calcified meningioma brain tumor, which later grew in size.

Due to the calcified state of the tumor, surgical removal has been deemed too dangerous, leaving Jones to endure chronic pain and other symptoms.

The complaint alleges that Pfizer and associated companies failed to thoroughly investigate and warn about the risks of long-term Depo-Provera use, which includes potential links to meningioma.

The lawsuit is part of a growing number of Depo-Provera lawsuits filed across the U.S.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are still accepting new clients. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to find out if you qualify for a claim instantly.

Pfizer and its co-defendants are facing nine allegations in a federal lawsuit filed in California.

The charges include Failure to Warn, Design Defect, Negligence, Negligent Failure to Warn, Negligent Design Defect, Negligent Misrepresentation, Fraudulent Misrepresentation, Breach of Express Warranty, and Breach of Implied Warranty.

The lawsuit accuses Pfizer and its co-defendants of knowingly designing, manufacturing, and marketing a product that could lead to intracranial meningiomas without providing sufficient warnings to consumers.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are still accepting new clients. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

The ongoing Depo-Provera Lawsuits have brought attention to legal nuances regarding the statute of limitations in these cases.

There are two main reasons why the statute of limitations should not significantly affect individuals filing lawsuits for Depo-Provera-related injuries at this time.

First, the “discovery rule” applies across states and can extend the statute of limitations.

The principle delays the deadline for filing a lawsuit until the injured party becomes aware of the injury and its connection to a specific cause.

In the case of Depo-Provera, recent scientific studies have revealed a potential link between the drug and brain tumors, an association not widely known before these studies.

Given the recent emergence of this evidence, plaintiffs could not reasonably have been expected to link their conditions to Depo-Provera until now.

Additionally, the doctrine of fraudulent concealment may also apply.

This doctrine states if a defendant intentionally conceals crucial safety information, the statute of limitations can be paused.

Plaintiffs allege that Depo-Provera’s manufacturers actively suppressed knowledge of the drug’s risks by manipulating safety warnings and product labeling, making it challenging for consumers to understand the potential link between Depo-Provera and meningiomas.

The alleged concealment of safety information means plaintiffs may argue they were prevented from learning of these risks, effectively extending the timeline for filing lawsuits.

This combination of the discovery rule and fraudulent concealment may give plaintiffs a strong basis to counter statute of limitations concerns in the Depo-Provera Lawsuit, allowing time to pursue claims linked to their injuries.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are still accepting new clients. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to find out if you qualify for a claim instantly.

A French study has identified a connection between Depo-Provera injections and meningiomas, tumors that develop from the protective membranes surrounding the brain and spinal cord.

Common symptoms of meningiomas include Headaches, Vision changes, Seizures, Memory loss, and Dizziness

Additional research is necessary to determine why Depo-Provera may contribute to an increased risk of tumor growth.

Given that 74 million women worldwide have used the drug, the potential scope of this litigation could be substantial.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are still accepting new clients. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

A 2020 review of 47 meningioma lawsuits has drawn the attention of legal experts investigating claims involving women who used Depo-Provera.

The analysis revealed that failure to diagnose was the primary issue in 68.1% of these cases.

Should a connection between Depo-Provera and an increased risk of meningiomas be established, legal analysts predict that settlement amounts could reach several hundred thousand dollars.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are still accepting new clients. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to instantly find out if you qualify for a claim.

Depo-Provera encountered numerous FDA rejections during the 1970s and 1980s before ultimately receiving approval in 1992.

Since then, the contraceptive has been linked to decreased bone density and notable side effects after discontinuation.

Recent studies have raised concerns about a possible connection between Depo-Provera and brain tumors, further amplifying the health risks associated with its use.

If you or a loved one developed a brain tumor after using Depo-Provera, you may be entitled to seek compensation through a Depo-Provera Lawsuit. 

Our lawyers are still accepting new clients. 

Contact our Depo-Provera Lawyers today for a free consultation, or use the chatbot on this page to find out if you qualify for a claim instantly.